Elios' Phase IIb Melanoma Data Are Promising, But Present Tricky Issues For Phase III Vaccine Study
Executive Summary
The biotech’s personalized vaccine shows it can reduce the risk of melanoma recurrence by 50% in the per-treatment population, but Phase III will need to demonstrate a similar benefit in an intent-to-treat population.